15.5 Million Adults Had Current ADHD Diagnosis in 2023
By Elana Gotkine HealthDay Reporter
TUESDAY, Oct. 15, 2024 -- An estimated 15.5 million U.S adults had a current diagnosis of attention-deficit/hyperactivity disorder (ADHD) in 2023, according to research published in the Oct. 10 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Brooke S. Staley, Ph.D., from the CDC in Atlanta, and colleagues estimated the prevalence of ADHD diagnosis and treatment among U.S. adults using data from the National Center for Health Statistics Rapid Surveys System collected during October to November 2023.
The researchers found that based on self-report, an estimated 15.5 million U.S. adults (6.0 percent) had a current diagnosis of ADHD in 2023; about half received the diagnosis at age 18 years or older. In the previous year, 36.5 percent of adults with ADHD were not receiving any treatment, while one-third were receiving both medication and counseling or behavioral treatment. Of the approximately one-third of adults with ADHD who took a stimulant medication to treat their ADHD, 71.5 percent had difficulty filling their prescription because it was unavailable. About half of adults with ADHD have ever used telehealth for ADHD-related services.
"Results highlight the magnitude of ADHD as a public health issue across the life course," the authors write. "Although the majority of adults with current ADHD received counseling or medication treatment for their ADHD in the previous year, approximately one-third did not receive any type of treatment."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Helping Others Linked to Higher Level of Cognitive Function
THURSDAY, Aug. 21, 2025 -- Helping others, both via formal volunteering and informal helping, is associated with higher levels of cognitive function and slower cognitive decline...
TAR-200 Monotherapy Promising for BCG-Unresponsive Bladder Cancer
THURSDAY, Aug. 21, 2025 -- For patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC), an intravesical...
Work-Related Income Drops for Parents of Children Diagnosed With Type 1 Diabetes
THURSDAY, Aug. 21, 2025 -- Work-related income decreases sharply for mothers and fathers of children diagnosed with type 1 diabetes, with similar effects across sociodemographic...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.